Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letermovir for CMV Prevention in HSCT Based on mNGS
NCT06021210Phase 2Unknown
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Jul 2022
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of letermovir in cytomegalovirus infection (CMV), sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: Incidence of clinically significant CMV infection with letermovir prevention after HSCT at 24 weeks. Status: unknown.
02
Drugs
letermovir
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT06021210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06021210.